Beta-1,4-GalNAc-T Polyclonal Antibody

CSGALNACT1 (Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1) is a Protein Coding gene. Diseases associated with CSGALNACT1 include bell's palsy. Among its related pathways are Defective B3GAT3 causes JDSSDHD and Metabolism. GO annotations related to this gene include glucuronosyltransferase activity and glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity. An important paralog of this gene is B4GALNT4.

Introducing the Beta-1,4-GalNAc-T Polyclonal Antibody, a cutting-edge scientific tool designed to facilitate advanced research in the field of glycobiology. This meticulously developed antibody is specifically engineered to target and detect the Beta-1,4-GalNAc-T enzyme, enabling researchers to gain valuable insights into its intricate biological functions.

Crafted with utmost precision and utilizing state-of-the-art technology, this polyclonal antibody exhibits exceptional specificity and sensitivity, ensuring accurate and reliable results. Its high affinity for the Beta-1,4-GalNAc-T enzyme allows for precise detection and quantification, enabling researchers to delve deeper into the complex mechanisms underlying glycosylation processes.

The Beta-1,4-GalNAc-T Polyclonal Antibody boasts an extensive range of applications, making it an indispensable asset in various scientific disciplines. From fundamental studies elucidating glycosylation pathways to clinical investigations exploring disease mechanisms, this antibody serves as an invaluable tool for researchers seeking to unravel the intricate world of glycobiology.

Furthermore, this antibody is meticulously purified and validated to meet the highest quality standards, ensuring optimal performance and reproducibility. Its robust and reliable nature guarantees consistent and accurate results, empowering researchers to confidently pursue their scientific endeavors.

In summary, the Beta-1,4-GalNAc-T Polyclonal Antibody represents a breakthrough in glycobiology research, offering unparalleled specificity, sensitivity, and versatility. With its exceptional performance and meticulous design, this antibody is poised to revolutionize the field, enabling researchers to unravel the complexities of glycosylation processes and pave the way for groundbreaking discoveries.